Cargando…
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer
BACKGROUND: The influence of the tumor microenvironment and tumor-stromal interactions on the heterogeneity of response within breast cancer subtypes have just begun to be explored. This study focuses on patients with estrogen receptor-positive/human epidermal growth factor receptor 2-positive (ER+/...
Autores principales: | Brodsky, Alexander S., Xiong, Jinjun, Yang, Dongfang, Schorl, Christoph, Fenton, Mary Anne, Graves, Theresa A., Sikov, William M., Resnick, Murray B., Wang, Yihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835834/ https://www.ncbi.nlm.nih.gov/pubmed/27090210 http://dx.doi.org/10.1186/s12885-016-2302-5 |
Ejemplares similares
-
Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer
por: Zhao, Chaohui Lisa, et al.
Publicado: (2019) -
ColXα1 is a stromal component that colocalizes with elastin in the breast tumor extracellular matrix
por: Wang, Yihong, et al.
Publicado: (2018) -
Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy
por: ÇAVDAR, Eyyüp, et al.
Publicado: (2022) -
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014) -
Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
por: Sevcikova, Katarina, et al.
Publicado: (2013)